|
General model
|
All participants (n = 28)
|
Patient Association (n = 4)
|
Physicians (n = 6)
|
Health economics (n = 7)
|
Hospital pharmacy (n = 5)
|
Health Authorities (n = 6)
|
|---|
|
Beta (coefficient)
|
Standard error
|
Z-value
|
p. value
|
Odds ratio
|
Rel. Imp (%)
|
Rel. Imp (%)
|
Rel. Imp (%)
|
Rel. Imp (%)
|
Rel. Imp
|
Rel. Imp (%)
|
|---|
|
HRQoL
|
− 1.011
|
0.069
|
− 14.742
|
< 0.001
|
0.364
|
23.53
|
14.27
|
20.55
|
25.11
|
22.35
|
21.83
|
|
Efficacy
|
− 0.614
|
0.067
|
− 9.175
|
< 0.001
|
0.541
|
14.64
|
13.23
|
15.05
|
8.86
|
17.70
|
10.73
|
|
Availability of treatment alternatives
|
− 0.552
|
0.065
|
− 8.466
|
< 0.001
|
0.576
|
13.51
|
11.00
|
9.92
|
6.00
|
16.43
|
19.39
|
|
Disease severity
|
0.514
|
0.065
|
7.907
|
< 0.001
|
1.672
|
12.62
|
13.93
|
11.62
|
14.82
|
8.89
|
5.27
|
|
Avoided costs
|
− 0.452
|
0.064
|
− 7.020
|
< 0.001
|
0.636
|
11.21
|
11.55
|
10.45
|
13.06
|
9.27
|
6.90
|
|
Age of target population
|
− 0.499
|
0.103
|
− 4.854
|
< 0.001
|
0.607
|
7.75
|
6.55
|
8.20
|
2.15
|
8.22
|
10.16
|
|
Safety (seriousness of AE)
|
− 0.303
|
0.103
|
− 2.956
|
0.003
|
0.738
|
4.72
|
8.70
|
5.49
|
4.15
|
1.50
|
1.10
|
|
Quality of evidence
|
− 0.151
|
0.063
|
− 2.392
|
0.017
|
0.860
|
3.82
|
3.91
|
7.21
|
2.44
|
4.50
|
1.05
|
|
Target population
|
− 0.125
|
0.064
|
− 1.952
|
0.051*
|
0.883
|
3.12
|
2.62
|
0.38
|
2.13
|
3.61
|
7.26
|
|
Economic burden of the disease
|
0.103
|
0.065
|
1.568
|
0.117
|
1.108
|
2.50
|
3.15
|
3.78
|
2.97
|
2.43
|
2.78
|
|
Cost of treatment
|
0.072
|
0.066
|
1.086
|
0.278
|
1.074
|
1.73
|
2.34
|
2.57
|
4.72
|
0.79
|
4.88
|
|
Cost-effectiveness
|
− 0.054
|
0.103
|
− 0.518
|
0.604
|
0.948
|
0.83
|
7.57
|
2.83
|
9.46
|
2.04
|
6.15
|
|
Safety (AE frequency)
|
− 0.002
|
0.103
|
− 0.017
|
0.986
|
0.998
|
0.03
|
1.19
|
1.73
|
4.12
|
2.25
|
2.52
|
- *p = 0.042 (< 0.05) in the reduced model. In bold, relevant criteria for decision-making. AE: adverse events; HRQoL: health-related quality of life; Rel. Imp.: relative importance
